Logo Université Laval Logo Université Laval
International Chair on Cardiometabolic Risk
My Healthy Waist

Documentation centre

1585-1596 of 1735 results
Page 133 of 145
Key Publications August 29, 2012

Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.

J Am Coll Cardiol 2012;59:2058-64

Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS
Lipids/Lipoproteins Prevention
Key Publications August 10, 2012

Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy.

Heart 2012;98:780-5

Ray K, Wainwright NW, Visser L, Witteman J, Breteler M, Ambegaonkar B, Hofman A, Stricker B, Wareham N, Khaw KT, Sandhu M
Lipids/Lipoproteins Prevention
Key Publications August 6, 2012

Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: the Cardiovascular Risk in Young Finns Study.

Circulation 2012;125:1971-8

Laitinen TT, Pahkala K, Magnussen CG, Viikari JS, Oikonen M, Taittonen L, Mikkilä V, Jokinen E, Hutri-Kähönen N, Laitinen T, Kähönen M, Lehtimäki T, Raitakari OT, Juonala M
Age Prevention
Key Publications August 6, 2012

Ideal cardiovascular health: start young, finish strong.

Circulation 2012;125:1955-7

Ford ES
Age Prevention
Key Publications August 6, 2012

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.

Circulation 2012;125:1979-87

Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD
Lipids/Lipoproteins Prevention
Key Publications August 6, 2012

Reducing residual risk in secondary prevention of cardiovascular disease.

Circulation 2012;125:1958-60

Stone NJ
Lipids/Lipoproteins Prevention
Key Publications August 3, 2012

Cardiovascular primary prevention: how high should we set the bar?

Arch Intern Med 2012;172:656-9

Prasad V, Vandross A
Prevention
Key Publications August 1, 2012

Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker.

Heart 2012; 98:683-90

Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, Grobbee DE
Epidemiology Prevention
Key Publications July 23, 2012

Impact of lower range of prehypertension on cardiovascular events in a general population: the Hisayama Study.

J Hypertens 2012;30:893-900

Fukuhara M, Arima H, Ninomiya T, Hata J, Yonemoto K, Doi Y, Hirakawa Y, Matsumura K, Kitazono T, Kiyohara Y
Hypertension Prevention
Key Publications July 23, 2012

Current challenges in the clinical management of hypertension.

Nat Rev Cardiol 2011;9:267-75

Ruilope LM
Hypertension Prevention
Key Publications July 23, 2012

Hypertension. Impact of having 'Prehypertension'.

Nat Rev Cardiol 2012;9:257

Mearns BM
Hypertension Prevention
Key Publications July 17, 2012

Evidence-based use of statins for primary prevention of cardiovascular disease.

Am J Med 2012;125:440-6

Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS
Lipids/Lipoproteins Prevention
of 145